Answer
Fluconazole, a moderate CYP2C9 and CYP3A4 inhibitor, increases erdafitinib exposure, with mean Cmax and AUC reaching 121% and 148%, respectively, of those with erdafitinib alone, potentially increasing drug-related toxicity.
Sources for this answer
- Balversa 3mg film-coated tabletsJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.5 Interaction with other medicinal products · Version 3Document updated
Sources checked